JP4887144B2 - バベシアワクチン - Google Patents

バベシアワクチン Download PDF

Info

Publication number
JP4887144B2
JP4887144B2 JP2006518230A JP2006518230A JP4887144B2 JP 4887144 B2 JP4887144 B2 JP 4887144B2 JP 2006518230 A JP2006518230 A JP 2006518230A JP 2006518230 A JP2006518230 A JP 2006518230A JP 4887144 B2 JP4887144 B2 JP 4887144B2
Authority
JP
Japan
Prior art keywords
protein
canis
nucleic acid
vaccine
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2006518230A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008500802A5 (enExample
JP2008500802A (ja
Inventor
カルシー，ベルナール・ピエール・ドミニク
ゴランフロ，アンドレ・フランソワ
シエツターズ，テオドルス・ペトルス・マリア
シーブルリユ，プリスカ・レテイシア
ムブリ，カリナ
ドウポア，デルフイーヌ
Original Assignee
インターベツト・インターナシヨナル・ベー・ベー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インターベツト・インターナシヨナル・ベー・ベー filed Critical インターベツト・インターナシヨナル・ベー・ベー
Publication of JP2008500802A publication Critical patent/JP2008500802A/ja
Publication of JP2008500802A5 publication Critical patent/JP2008500802A5/ja
Application granted granted Critical
Publication of JP4887144B2 publication Critical patent/JP4887144B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56905—Protozoa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A61K39/018—Babesia antigens, e.g. Theileria antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/20—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2006518230A 2003-07-10 2004-07-12 バベシアワクチン Expired - Fee Related JP4887144B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03077178 2003-07-10
EP03077178.6 2003-07-10
PCT/EP2004/051454 WO2005012343A1 (en) 2003-07-10 2004-07-12 Babesia vaccines

Publications (3)

Publication Number Publication Date
JP2008500802A JP2008500802A (ja) 2008-01-17
JP2008500802A5 JP2008500802A5 (enExample) 2011-01-27
JP4887144B2 true JP4887144B2 (ja) 2012-02-29

Family

ID=34112460

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006518230A Expired - Fee Related JP4887144B2 (ja) 2003-07-10 2004-07-12 バベシアワクチン

Country Status (8)

Country Link
US (1) US7722879B2 (enExample)
EP (1) EP1646647A1 (enExample)
JP (1) JP4887144B2 (enExample)
AU (1) AU2004260737B2 (enExample)
BR (1) BRPI0412419A (enExample)
CA (1) CA2531329A1 (enExample)
WO (1) WO2005012343A1 (enExample)
ZA (1) ZA200600180B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7682619B2 (en) 2006-04-06 2010-03-23 Cornell Research Foundation, Inc. Canine influenza virus
WO2012089748A1 (en) * 2010-12-29 2012-07-05 Intervet International B.V. Canine babesiosis vaccine antigen
EP2626365A1 (en) * 2012-02-10 2013-08-14 MegaCor Diagnostik GmbH Compounds and methods for the diagnosis of babesia canis canis infection
RU2583139C1 (ru) * 2014-11-13 2016-05-10 Федеральное государственное бюджетное научное учреждение "Прикаспийский зональный научно-исследовательский ветеринарный институт" Способ пролонгированной химиопрофилактики пироплазмидозов крупного рогатого скота
DK180392B1 (en) 2019-09-09 2021-03-12 Apple Inc Techniques for managing display usage
US20230190905A1 (en) * 2021-09-28 2023-06-22 The United States Of America, As Represented By The Secretary Of Agriculture Transmission-blocking vaccine against babesia
WO2025118050A1 (pt) * 2023-12-04 2025-06-12 Laboratório Bio-Vet Ltda Antígeno vacinal quimérico com ação tríplice contra erliquiose, anaplasmose e babesiose canina, vetor de expressão, célula recombinante, composição vacinal, kit de diagnóstico, método de tratamento e uso de proteína quimérica

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA906667B (en) 1989-08-23 1991-06-26 Commw Scient Ind Res Org Antigens and polypeptides derived from babesia(12d3 antigen)
EP1050541A1 (en) 1999-04-29 2000-11-08 Akzo Nobel N.V. Babesia vaccine
AU2001250572A1 (en) * 2000-04-07 2001-10-23 Epigenomics Ag Detection of single nucleotide polymorphisms (snp's) and cytosine-methylations
EP1238983A1 (en) 2001-03-06 2002-09-11 Akzo Nobel N.V. "Babesia canis vaccine"

Also Published As

Publication number Publication date
AU2004260737B2 (en) 2009-09-10
BRPI0412419A (pt) 2006-08-22
CA2531329A1 (en) 2005-02-10
ZA200600180B (en) 2007-02-28
WO2005012343A1 (en) 2005-02-10
AU2004260737A1 (en) 2005-02-10
US7722879B2 (en) 2010-05-25
EP1646647A1 (en) 2006-04-19
US20070041991A1 (en) 2007-02-22
JP2008500802A (ja) 2008-01-17

Similar Documents

Publication Publication Date Title
JP2003000276A (ja) ローソニア・イントラセルラリス・ワクチン
JP4887144B2 (ja) バベシアワクチン
US9346862B2 (en) Canine babesiosis vaccine antigen
JPH08127593A (ja) 家禽コクシジウム症ワクチン
US7799330B2 (en) Piroplasmid vaccine
CA2285136C (en) Coccidiosis vaccines
EP1238983A1 (en) "Babesia canis vaccine"
US6808714B2 (en) Detection of sarcocystis neurona
US7090849B2 (en) Babesia canis vaccine
JP2005535350A (ja) ストレプトコッカス・ユベリス蛋白質、前記蛋白質をコードする核酸配列及び乳腺炎ワクチンにおけるその使用
CA2548750A1 (en) Lawsonia intracellularis 26 kd subunit vaccine
MXPA06002871A (en) Piroplasmid vaccine
IL147888A (en) Vaccine for rabies in animals from the canine family and methods for its preparation
MXPA99009162A (en) Coccidiosis vaccines

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100601

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100727

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100803

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101130

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20101130

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110607

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20110616

RD13 Notification of appointment of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7433

Effective date: 20110630

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110816

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111003

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20111206

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20111212

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20141216

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees